Shannon Bordes, APRN
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 24.8% of the total. Reporting peaked in 2024 at $2,146 and has fallen 58.7% since, to $887 in 2025. Among family clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Ipsen Biopharmaceuticals, Inc$473
- Takeda Pharmaceuticals U.S.A., Inc.$457
- Intercept Pharmaceuticals, Inc.$380
- Sanofi$363
- Regeneron Healthcare Solutions, Inc.$227
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,694100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 71 | $1,166 |
| Ipsen Biopharmaceuticals, Inc | 9 | $473 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $457 |
| Intercept Pharmaceuticals, Inc. | 8 | $380 |
| Sanofi | 9 | $363 |
| Regeneron Healthcare Solutions, Inc. | 13 | $227 |
| Madrigal Pharmaceuticals | 6 | $213 |
| Johnson & Johnson | 3 | $191 |
| Aimmune Therapeutics, Inc. | 1 | $152 |
| Lilly USA, LLC | 6 | $151 |
| Hologic Inc | 2 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $134 |
| Bayer | 1 | $120 |
| Pfizer | 4 | $102 |
| Gilead | 1 | $97 |
| Ardelyx, Inc. | 4 | $79 |
| Phathom Pharmaceuticals, Inc. | 3 | $61 |
| Celltrion USA Inc. | 2 | $40 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| Bristol Myers Squibb | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Shield Therapeutics Inc | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $15 |
| Digestive Care, Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,694 in reported general payments places this provider in the 90th percentile of 809 family providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 24 | $659,861 |
| OcalivaObeticholic Acid | 11 | $94,253 |
| ZenpepLipase/Protease/Amylase | 41 | $79,399 |
| XifaxanRifaximin | 24 | $77,003 |
| LinzessLinaclotide | 71 | $63,904 |
| CreonLipase/Protease/Amylase | 25 | $29,729 |
| Mesalamine | 33 | $18,227 |
| MotegrityPrucalopride Succinate | 15 | $10,419 |
| TrulancePlecanatide | 15 | $7,925 |
| Budesonide DrBudesonide | 34 | $4,921 |
| Omeprazole | 314 | $4,234 |
| Cholestyramine LightCholestyramine | 28 | $3,757 |
| Dexlansoprazole DrDexlansoprazole | 18 | $3,703 |
| Sucralfate | 16 | $3,258 |
| CholestyramineCholestyramine (With Sugar) | 41 | $3,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $191 | $659,86124 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $380 | $94,25311 claims |
| AbbVieLinzess, Creon | $1,166 | $93,63396 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $134 | $84,92839 claims |
| Aimmune Therapeutics, Inc.Zenpep | $152 | $79,39941 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $457 | $10,41915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Idaho.
Other family in Boise
- Jessica BraksiekBoise$41K
- Travis BlaserBoise$33K
- Devon MoserBoise$11K
- Jeffrey RobbinsBoise$9K
- Morgann EasonBoise$7K
- Lori RishelBoise$7K
- Heidi PetersBoise$7K
- Michelle ChinBoise$6K
- Nancy JordanBoise$6K
- Jillian VaughanBoise$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.